Archon Capital Management LLC raised its holdings in Vericel Corp (NASDAQ:VCEL) by 23.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,229,777 shares of the biotechnology company’s stock after buying an additional 612,773 shares during the period. Vericel accounts for about 8.8% of Archon Capital Management LLC’s portfolio, making the stock its largest holding. Archon Capital Management LLC owned about 9.25% of Vericel worth $17,602,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of VCEL. Perkins Capital Management Inc. boosted its holdings in shares of Vericel by 118.4% during the 3rd quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock worth $3,376,000 after buying an additional 305,000 shares during the period. JPMorgan Chase & Co. bought a new stake in Vericel in the 3rd quarter valued at about $328,000. EAM Investors LLC bought a new stake in Vericel in the 3rd quarter valued at about $943,000. First Washington CORP boosted its holdings in Vericel by 20.1% in the 4th quarter. First Washington CORP now owns 809,027 shares of the biotechnology company’s stock valued at $4,409,000 after purchasing an additional 135,600 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Vericel by 7.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock valued at $4,002,000 after purchasing an additional 88,645 shares during the period. Hedge funds and other institutional investors own 37.22% of the company’s stock.
VCEL has been the subject of a number of recent analyst reports. Ladenburg Thalmann Financial Services downgraded shares of Vericel from a “buy” rating to a “neutral” rating in a report on Tuesday, March 6th. Needham & Company LLC upped their price objective on shares of Vericel from $5.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, March 6th. BidaskClub upgraded shares of Vericel from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 7th. BTIG Research restated a “buy” rating and issued a $13.00 price target (up from $8.00) on shares of Vericel in a research report on Monday, March 5th. Finally, Piper Jaffray Companies upped their price target on shares of Vericel to $14.00 and gave the company an “overweight” rating in a research report on Monday, March 5th. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $14.00.
Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Monday, March 5th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.13. The business had revenue of $23.35 million during the quarter. Vericel had a negative net margin of 27.04% and a negative return on equity of 98.77%. sell-side analysts forecast that Vericel Corp will post -0.14 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Archon Capital Management LLC Has $17.60 Million Stake in Vericel Corp (NASDAQ:VCEL)” was originally reported by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://baseballnewssource.com/2018/03/14/archon-capital-management-llc-acquires-612773-shares-of-vericel-corp-vcel/1890523.html.
Vericel Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.